Tevogen Bio Secures Strategic Facility Agreement With CD8 To Advance GMP Production And R&D

Tevogen Bio, a clinical-stage biotech company listed on the, has signed an agreement with CD8 Technology Services LLC to develop or acquire a turn-key facility. This facility will support Tevogen Bio’s in-house pre-clinical research and GMP (Good Manufacturing Practice) cell therapy production, marking a significant step in the company's infrastructure expansion. 

“This milestone represents a significant step forward in Tevogen Bio’s infrastructure expansion to support the advancement of its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics,” commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “In addition, as we continue executing our mission to help patients, we’re also exploring additional ways to recognise our real, long-term shareholders.”

Under the agreement, Tevogen Bio will oversee staffing and operations for the facility, which is critical in the company’s strategy to streamline development timelines, enhance flexibility, and control production costs. This move will help Tevogen Bio bypass substantial capital investment hurdles often accompanying building large-scale GMP operations. The agreement begins with a 12-month term and will automatically renew, aligning with Tevogen’s previously stated financial projections.

CD8 Technology Services maintains ties to Dr. Manmohan Patel, who possesses substantial ownership stakes in Tevogen Bio. The agreement settles all elements discussed in prior letters of intent, and additional information about services, costs, and timelines will be stated within upcoming work orders.